Nivolumab fails to hit primary endpoint in brain tumour trial

The CheckMate -548 Phase III trial, investigating nivolumab plus current standard of care in patients with newly diagnosed glioblastoma multiforme, has been stopped early as it became clear that the primary endpoint of improved overall survival would not be met.

Source:

Biospace Inc.